Imidomics

IMIDomics is a biopharmaceutical company focused on discovering and developing first-in-class medicines for immune-mediated inflammatory diseases (IMIDs). Its stated aim is to serve patients who fail to respond to, or develop resistance against, currently available IMID therapies, and to develop markers that stratify which patients are most likely to respond to each of its drug candidates.

The company's approach couples a proprietary clinical and biomolecular patient dataset with bioinformatics to select drug targets and patient populations. It maintains direct, ongoing patient access across eight IMIDs and an IMID-Biobank. According to the company, the underlying dataset spans more than 17 years of data and sample collection through over 130 recruiting centers and more than 300 investigators, and includes more than 17,000 IMID patients and control subjects, more than 10,000 clinical variables, more than 2 million clinical and epidemiological data points, and more than 1 million biological specimens (blood and relevant tissues). Both cross-sectional and longitudinal data are collected to reflect disease evolution over time.

The eight diseases currently targeted are systemic lupus erythematosus, ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriasis, psoriatic arthritis, atopic dermatitis and Sjogren's syndrome.

Founding story

Fred Craves, Ph.D., has been involved with IMIDomics since the company was founded and serves as Executive Chairman and Chief Executive Officer. The company's website features an account from its founder on the origins of IMIDomics. Craves previously founded the life science investment firm Bay City Capital and founded Reliant Pharmaceuticals, which was sold to GlaxoSmithKline in 2007. He holds a BS in Biology from Georgetown University and a Ph.D. in Pharmacology and Toxicology from the University of California, San Francisco, has been named to the Forbes Midas List, and serves on the boards of IMIDomics, Madrigal Pharmaceuticals, Synchronicity Pharma and the Gladstone Foundation.

Business model

IMIDomics operates as a therapeutics discovery and development company, building an internal pipeline of first-in-class IMID drug candidates from its proprietary patient dataset and biobank. It also positions its data and profiling platform for partnerships, referencing collaborators and advisors spanning patient data and sample collection, drug discovery and development, and pharmaceutical organizations, and it maintains a partnerships channel for external parties.

Traction

Reported platform scale includes more than 17 years of data and sample collection, more than 130 recruiting centers, more than 300 investigators, more than 17,000 IMID patients and control subjects, more than 10,000 clinical variables, more than 2 million clinical and epidemiological data points, and more than 1 million biological specimens. The company describes partners and advisors across patient data collection, drug discovery and development, and pharmaceutical companies, and notes collaboration relating to advancing next-generation medicines for IBD patients.